{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:16:02Z","timestamp":1781716562868,"version":"3.54.5"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Object<\/jats:title><jats:p>The treatment of multiple sclerosis (MS) with high-efficacy disease-modifying therapies (HE-DMTs) may lead to better long-term outcomes for patients. There is an ongoing debate about which patients should initially start with these treatments. The objective of this study was to assess the first symptoms at the time of MS diagnosis and to identify independent predictors of treatment switching to HE-DMTs in MS patients within 5 years after diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A single-center retrospective, observational study was conducted at tertiary MS center Vilnius University Hospital Santaros Klinikos, Lithuania. 319 patients newly diagnosed with relapsing MS who were initially treated with MS platform therapy between 2010 and 2019 were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the disease course, 26.65% of patients were switched from platform therapy to HE-DMTs within 5\u202fyears of follow-up. Factors associated with the need to switch therapies were younger age (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), shorter disease duration (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and higher progression index (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) at diagnosis, lower initial EDSS (<jats:italic>p<\/jats:italic>\u202f=\u202f0.003) and the presence of cerebellum and\/or brainstem symptoms (<jats:italic>p<\/jats:italic>\u202f=\u202f0.047). Younger age, shorter disease duration and cerebellar\/brainstem presentation at diagnosis remained statistically significant after logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Younger age, shorter disease duration and cerebellar\/brainstem presentation at diagnosis were consistently associated with the need to escalate platform.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1635618","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:22:29Z","timestamp":1759983749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of therapy switching to high-efficacy disease-modifying therapies in patients with multiple sclerosis: a single center, retrospective, observational study"],"prefix":"10.3389","volume":"16","author":[{"given":"Gytis","family":"Makarevi\u010dius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Kizlaitien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintaras","family":"Kaubrys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Giedraitien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs. immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different National Strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"17562864211019574","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","article-title":"Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis","volume":"269","author":"Filippi","year":"2022","journal-title":"J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"693017","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry","volume":"12","author":"Simonsen","year":"2021","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s00415-023-12137-8","article-title":"Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS registry","volume":"271","author":"Iaffaldano","year":"2024","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e00552","DOI":"10.1016\/j.neurot.2025.e00552","article-title":"First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis","volume":"22","author":"Toscano","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"105751","DOI":"10.1016\/j.msard.2024.105751","article-title":"Real-world evidence from Germany and the United States: treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis","volume":"88","author":"Papukchieva","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e70326","DOI":"10.1002\/brb3.70326","article-title":"Evolving patterns of initial RRMS treatment in Finland (2013-2022): insights from a Nationwide multiple sclerosis register","volume":"15","author":"Ahvenj\u00e4rvi","year":"2025","journal-title":"Brain Behav"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"17562864241237857","DOI":"10.1177\/17562864241237857","article-title":"Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis \u2013 real-world evidence from Germany","volume":"17","author":"Papukchieva","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/1352458519881558","article-title":"A roadmap to precision medicine for multiple sclerosis","volume":"26","author":"Chitnis","year":"2020","journal-title":"Mult Scler"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1177\/1352458517690618","article-title":"Age related multiple sclerosis severity score: disability ranked by age","volume":"23","author":"Manouchehrinia","year":"2017","journal-title":"Mult Scler"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40263-025-01164-w","article-title":"Treatment De-escalation in relapsing-remitting multiple sclerosis: an observational study","volume":"39","author":"M\u00fcller","year":"2025","journal-title":"CNS Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs. early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1274194","DOI":"10.3389\/fneur.2023.1274194","article-title":"Predictors of treatment switching in the big multiple sclerosis data network","volume":"14","author":"Spelman","year":"2023","journal-title":"Front Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1590\/0004-282x-anp-2022-s128","article-title":"How to choose initial treatment in multiple sclerosis patients: a case-based approach","volume":"80","author":"Ap\u00f3stolos","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"102813","DOI":"10.1016\/j.msard.2021.102813","article-title":"Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS","volume":"50","author":"Sorensen","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/13524585221139156","article-title":"Improving the decision to switch from first- to second-line therapy in multiple sclerosis: a dynamic scoring system","volume":"29","author":"Sabath\u00e9","year":"2023","journal-title":"Mult Scler"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple sclerosis severity score: using disability and disease duration to rate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"104803","DOI":"10.1016\/j.msard.2023.104803","article-title":"Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries","volume":"76","author":"Hrnciarova","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e636","DOI":"10.1212\/NXI.0000000000000636","article-title":"An argument for broad use of high efficacy treatments in early multiple sclerosis","volume":"7","author":"Stankiewicz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.msard.2020.102124","article-title":"Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)","volume":"42","author":"Patti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"647811","DOI":"10.3389\/fneur.2021.647811","article-title":"Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network","volume":"12","author":"Hillert","year":"2021","journal-title":"Front Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"101928","DOI":"10.1016\/j.msard.2020.101928","article-title":"Predictive medicine in multiple sclerosis: a systematic review","volume":"40","author":"Havas","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"102686","DOI":"10.1016\/j.msard.2020.102686","article-title":"First line treatment failure: predictive factors in a cohort of 863 relapsing remitting MS patients","volume":"48","author":"Ayrignac","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1177\/1352458518790390","article-title":"Determinants of therapy switch in multiple sclerosis treatment-na\u00efve patients: a real-life study","volume":"25","author":"Sacc\u00e0","year":"2019","journal-title":"Mult Scler"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"100307","DOI":"10.1016\/j.rcsop.2023.100307","article-title":"Assessing treatment switch among patients with multiple sclerosis: a machine learning approach","volume":"11","author":"Li","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"17562864241239740","DOI":"10.1177\/17562864241239740","article-title":"Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS registry","volume":"17","author":"Frahm","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00234-024-03483-z","article-title":"Correlation between MRI utilization and therapy switches in disease-modifying treatments for multiple sclerosis","volume":"66","author":"Naizer","year":"2024","journal-title":"Neuroradiology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.1111\/ene.70042","article-title":"De-escalation of disease-modifying therapy in multiple sclerosis-a Danish Nationwide cohort study","volume":"32","author":"Elberling","year":"2025","journal-title":"Eur J Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1007\/s00415-024-12584-x","article-title":"MS treatment de-escalation: review and commentary","volume":"271","author":"Selmaj","year":"2024","journal-title":"J Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"102893","DOI":"10.1016\/j.autrev.2021.102893","article-title":"Immunosenescence in multiple sclerosis: the identification of new therapeutic targets","volume":"20","author":"Dema","year":"2021","journal-title":"Autoimmun Rev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1212\/WNL.0000000000012354","article-title":"Effects of high- and low-efficacy therapy in secondary progressive multiple sclerosis","volume":"97","author":"Roos","year":"2021","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s13760-017-0828-1","article-title":"Long-term disability and progression in spinal onset multiple sclerosis","volume":"118","author":"Tiftikcioglu","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fneur.2022.874388","article-title":"Cerebellar and\/or brainstem lesions indicate poor prognosis in multiple sclerosis: a systematic review","volume":"13","author":"Yang","year":"2022","journal-title":"Front Neurol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10072-024-07767-3","article-title":"Assessment of the multiple sclerosis severity score and the age-related multiple sclerosis severity score as health indicators in a population-based cohort","volume":"46","author":"Bau","year":"2025","journal-title":"Neurol Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"123161","DOI":"10.1016\/j.jns.2024.123161","article-title":"Environmental factors related to multiple sclerosis progression","volume":"464","author":"Gouider","year":"2024","journal-title":"J Neurol Sci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1635618\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:22:30Z","timestamp":1759983750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1635618\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":45,"alternative-id":["10.3389\/fneur.2025.1635618"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1635618","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"article-number":"1635618"}}